Ultragenyx Pharmaceutical (NASDAQ:RARE) Downgraded to Strong Sell Rating by Wall Street Zen

Posted by Geri Gentry on May 12th, 2026

Wall Street Zen downgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) from a hold rating to a strong sell rating in a research report released on Monday morning.

A number of other research analysts also recently commented on the company. Barclays dropped their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Morgan Stanley lifted their target price on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, April 16th. The Goldman Sachs Group lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and cut their target price for the company from $61.00 to $25.00 in a research report on Tuesday, March 24th. Canaccord Genuity Group lowered their price objective on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. Finally, Weiss Ratings upgraded Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.41.

View Our Latest Analysis on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Stock Up 0.7%

RARE stock opened at $26.30 on Monday. The company has a market cap of $2.59 billion, a PE ratio of -4.30 and a beta of 0.39. The business has a 50-day simple moving average of $22.81 and a 200 day simple moving average of $26.68. Ultragenyx Pharmaceutical has a 52 week low of $18.29 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The firm’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period last year, the firm earned ($1.57) EPS. On average, analysts anticipate that Ultragenyx Pharmaceutical will post -4.61 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Theodore Alan Huizenga sold 1,632 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $37,209.60. Following the completion of the sale, the chief accounting officer owned 48,670 shares of the company’s stock, valued at approximately $1,109,676. This trade represents a 3.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the sale, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. This trade represents a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 111,522 shares of company stock worth $2,543,214 in the last quarter. 5.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the company. Assetmark Inc. grew its holdings in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,024 shares in the last quarter. Huntington National Bank grew its holdings in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares in the last quarter. Parallel Advisors LLC grew its holdings in Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,440 shares in the last quarter. Leonteq Securities AG grew its holdings in Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,333 shares in the last quarter. Finally, Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $39,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.